Gastroenterologia y hepatologia · 2016
IV Spanish Consensus Conference on Helicobacter pylori infection treatment.
Consensus StatementСтатьяКлинические рекомендацииСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gisbert Javier P, Molina-Infante Javier, Amador Javier, Bermejo Fernando, Bujanda Luis, Calvet Xavier, Castro-Fernández Manuel, Cuadrado-Lavín Antonio, Elizalde J Ignasi, Gene Emili, Gomollón Fernando, Lanas Ángel, Martín de Argila Carlos, Mearin Fermín, Montoro Miguel, Pérez-Aisa Ángeles, Pérez-Trallero Emilio, McNicholl Adrián G
Аннотация
Helicobacter pylori approximately infect 50% of Spanish population and causes chronic gastritis, peptic ulcer and gastric cancer. Until now, three consensus meetings on H.pylori infection had been performed in Spain (the last in 2012). The changes in the treatment schemes, and the increasing available evidence, have justified organizing the IVSpanish Consensus Conference (March 2016), focused on the treatment of this infection. Nineteen experts participated, who performed a systematic review of the scientific evidence and developed a series of recommendation that were subjected to an anonymous Delphi process of iterative voting. Scientific evidence and the strength of the recommendation were classified using GRADE guidelines. As starting point, this consensus increased the minimum acceptable efficacy of recommended treatments that should reach, or preferably surpass, the 90% cure rate when prescribed empirically. Therefore, only quadruple therapies (with or without bismuth), and generally lasting 14 days, are recommended both for first and second line treatments. Non-bismuth quadruple concomitant regimen, including a proton pump inhibitor, clarithromycin, amoxicillin and metronidazole, is recommended as first line. In the present consensus, other first line alternatives and rescue treatments are also reviewed and recommended.